Thomas Tedder

Thomas Tedder

Company: Duke University School of Medicine

Job title: Alter Geller Distinguished Professor for Research in Immunology


Thomas F. Tedder received his Ph.D. degree in Molecular Cell Biology from the University of Alabama at Birmingham in 1984, where he was an American Society for Microbiology President’s Fellow. He was a Damon Runyon-Walter Winchell Research Fellow at Harvard Medical School and Dana-Farber Cancer Institute, and joined the faculty in 1985, rising to Associate Professor and principal investigator in the Division of Tumor Immunology at Dana-Farber Cancer Institute. In 1993, Dr. Tedder became the inaugural Chairman and Professor of Duke University Medical Center’s Department of Immunology. He has also served as Director of the Duke Comprehensive Cancer Center Immunobiology Program, and numerous NIH, national, and international service and advisory committees. He was a Scholar of the Leukemia Society of America, and received the LeRoy Collins Distinguished Alumni Award, a NCI/NIH Shannon Award, the Stohlman Scholarship, the Leukemia Society’s highest award for research in the field of hematology/oncology, and the Alter Geller Professorship for Research in Immunology at Duke. His laboratory research originates from a deep interest in the role of B lymphocytes in cancer biology and autoimmune diseases, with a recent focus on regulatory B cell subsets and how they regulate autoimmunity and other diseases. He has authored over 400 scientific papers and was recognized as an ISI “100 Most-Cited Authors” in the field of Immunology. Dr. Tedder holds twenty-five patents issued in the United States. He founded Cellective Therapeutics, with the largest Series A financing in the southeast at that time, that was acquired by MedImmune/AstraZeneca, who continue to develop the Cellective pipeline of therapies, including inebilizumab. He subsequently founded Cellective BioTherapy, an ongoing biotechnology company. Dr. Tedder has and continues to serve as a consultant and SAB member of over twenty national and international biopharmaceutical companies and private foundations. 


Live Q&A 10:40 am

Using this opportunity to ask your expert speakers those burning questions.Read more

day: Day One

Keynote: Past, Present and Future of B Cell Directed Therapies 9:10 am

B Cells are significant therapeutic targets for autoimmune disease Pro-inflammatory and regulatory B cell subsets balance autoimmunity B cell functions and autoantibody products as new therapy targetsRead more

day: Day One

Chair’s Opening Remarks 9:00 am

Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.